Research ArticleArticle

Treating Adult Cancer Pain in Primary Care

Francine Rainone
The Journal of the American Board of Family Practice November 2004, 17 (suppl 1) S48-S56; DOI: https://doi.org/10.3122/jabfm.17.suppl_1.S48

References

  1. ↵
    Portenoy RK. Contemporary diagnosis and management of pain in oncologic and AIDS patients, 3rd ed. Newtown (PA): Handbooks in Health Care; 2000. p. 7–9.
  2. ↵
    Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994; 9: 772–8.
    OpenUrl
  3. ↵
    Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief: a 10 year prospective study. Pain 1995; 63: 65–76.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Cleeland CS, Gonin R, Hatfield AK, et al. The prevalence of pain in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592–6.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Merskey H. Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms. Pain 1979; (Suppl 3): S217.
  6. ↵
    Galer BS, Dworkin RH. A clinical guide to neuropathic pain. Minneapolis (MN): Healthcare Information Programs; 2000. p. 4–6.
  7. ↵
    Cancer pain relief and palliative care. Geneva, Switzerland: World Health Organization; 1996.
  8. ↵
    Kaye P. Notes on symptom control in hospice and palliative care. Essex (CT): Hospice Education Institute; 1998. p. 217.
  9. ↵
    Ashburn MA, Lipman AG, Carr D, Rubingh C. Principles of analgesia use in the treatment of acute pain and cancer pain, 5th ed. Glenview (IL): American Pain Society; 2003. p. 34–6.
  10. ↵
    Janjan NA. Radiotherapeutic management of spinal metastases. J Pain Symptom Manage 1996; 11: 47–56.
    OpenUrlPubMed
  11. ↵
    Tryciecky EW, Gottschalk A, Ludema K. Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med 1997; 27: 142–51.
    OpenUrlCrossRefPubMed
  12. ↵
    Arcangeli G, Micheli A, Arcangeli G, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol 1989; 14: 95–101.
    OpenUrlCrossRefPubMedWeb of Science
  13. Bates T, Yarnold JR, Blitzer P, et al. Bone metastasis consensus statement. Int J Radiat Oncol Biol Phys 1992; 23: 215–6.
    OpenUrlPubMed
  14. Hoskin PJ. Radiotherapy in the management of bone pain. Clin Orthop 1995; (312): 105–19.
  15. ↵
    Pereira J. Management of bone pain. In: Portenoy RK, Bruera E, editors. Topics in palliative care. Vol. 3. Cambridge (UK): Oxford University Press; 1998. p. 79–116.
  16. ↵
    Hong D, Byers MR, Oswald RJ. Dexamethasone treatment reduces sensory neuropeptides and nerve sprouting reactions in injured teeth. Pain 1993; 55: 171–81.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 111: 735–40.
    OpenUrl
  18. ↵
    Giammarile F, Mognetti T, Resche I. Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Med 2001; 45: 78–83.
    OpenUrlPubMed
  19. ↵
    Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer [published erratum appears in BMJ 2004;328:384]. BMJ 2003; 327: 469.
    OpenUrlAbstract/FREE Full Text
  20. Berenson JR, Hillner BE, Kyle RA, et al. American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719–36.
    OpenUrlAbstract/FREE Full Text
  21. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434–7.
    OpenUrlAbstract/FREE Full Text
  22. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378–91.
    OpenUrlAbstract/FREE Full Text
  23. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082–90.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Deys RA, Diehl AK. Cancer as a cause of back pain: frequency, clinical presentation and diagnostic strategies. Gen Intern Med 1988; 3: 230–8.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995; 15;32: 959–67.
    OpenUrl
  26. Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy of spinal cord compression caused by breast cancer: report of a prospective trial. Int J Radiat Oncol Biol Phys 1992; 24: 301–6.
    OpenUrlPubMed
  27. Heimdal K, Hirschberg H, Slettebo H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol 1992; 12: 141–4.
    OpenUrlPubMed
  28. Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients. Cancer 1991; 67: 1311–7.
    OpenUrlCrossRefPubMedWeb of Science
  29. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A: 22–7.
  30. ↵
    Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol 1998; 16: 1613–23.
    OpenUrlAbstract/FREE Full Text
  31. Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Saf 1994; 11: 163–78.
    OpenUrlPubMedWeb of Science
  32. Vecht CJ, Haaxma-Reiche H, van Putten W, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989; 39: 1255–7.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Laval G, Girardier J, Lassauniere JM, et al. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Palliat Med 2000; 14: 3–10.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    McQuay H, Carrroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047–52.
    OpenUrlAbstract/FREE Full Text
  35. Yajnik S, Singh GP, Singh G, Kumar M. Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage 1992; 7: 209–13.
    OpenUrlCrossRefPubMedWeb of Science
  36. Swerdlow M. Anticonvulsant drugs and chronic pain. Clin Neuropharmacol 1984; 7: 51–82.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    Rosenberg JM, Harrell C, Ristic H, Werner RA, de Rosayro AM. The effect of gabapentin on neuropathic pain. Clin J Pain 1997; 13: 251–5.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants for neuropathic pain. Pain 1996; 68: 217–27.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Elja K, Tiina T, Pertti NJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996; 64: 293–302.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Ventafridda V, Bonezzi C, Caraceni A, et al. Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone. Ital J Neurol Sci 1987; 8: 579–87.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Evidence report/technology assessment: number 7. Treatment of depression—newer pharmacotherapies. Rockville (MD): Agency for Health Care Policy and Research; 1999.
  42. ↵
    Hippisley-Cox J, Pringle M, Hammersley V, et al. Antidepressants as risk factor for ischemic heart disease: case-control study in primary care. BMJ 2001; 323: 666–9.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108: 2–8.
    OpenUrlPubMedWeb of Science
  44. ↵
    Nelson JC, Mazure C, Bowers MD, et al. Synergistic effects of fluoxetine and desipramine: a prospective study. Presented at the 21st meeting of the Collegium International Neuro-psychopharmacologicum Congress; 1998 Jul 12–16; Glasgow, Scotland.
  45. ↵
    Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989; 50: 447–9.
    OpenUrlPubMedWeb of Science
  46. ↵
    Marshall KA. Managing cancer pain: basic principles and invasive treatments. Mayo Clinic Proc 1996; 71: 472–7.
    OpenUrlCrossRefPubMed
  47. ↵
    Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 2000; 7: 149–56.
    OpenUrlPubMed
  48. ↵
    Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995; 80: 290–9.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section